The strength of our management team is in the experience of our scientists and the success of our business talent. They are backed by a dedicated group of individuals, principally scientists by training, wholly focused on applying advanced technologies to best serve every customer.
Mr. Edelman has been the CEO of Radix since January 2014, and has over 30 years experience in managing and profitably growing early stage businesses both in the software and biotech industries.
Previous to Mr. Edelman's involvement with Radix, Scott was one of the founding members and CEO of AdiCyte Inc., a Tucson-based, start-up for adipose tissue and stem cell banking starting in late 2011. From 2003 through 2008, Mr. Edelman was CEO of CellzDirect, a hepatic cell product and contract research organization that grew profitability from zero to $19 million in revenues that was sold to Life Technologies in 2008.
Mr. Edelman has a BS in Business from Pennsylvania State University, is an active angel investor in numerous early stage enterprises, and resides in Tucson, Arizona.
Kerry Oliver, Ph.D.
President, Chief Scientific Officer
In late 2001, Kerry co-founded Radix BioSolutions to satisfy unmet customer needs for custom molecular and immunoassay development, validation, and manufacturing. The pride of his career nearly 20 years later, Radix products continue to be used for customer’s in-house research, clinical trials, and environmental threat assessment and testing.
In 1997, Kerry joined the R&D department at Luminex during its initial development of the xMAP® diagnostic platform. Among his initial responsibilities at Luminex was to lead a team of assay development scientists in showcasing the capabilities of the platform to early adopters. In addition, he served as a liaison with key customers and strategic partners to expedite adoption and commercialization of the platform.
Looking back, Kerry has over thirty years of academic, government, and industry experience in assay development. His work has spanned a broad range of disciplines including immunology and signal transduction biochemistry, diagnostic device development, and CRO services in support of various stages of therapeutic development. Following his Ph.D. in immunology from the University of Texas Southwestern Medical Center at Dallas under the direction of Dr. Ellen Vitetta, Kerry received his postdoctoral training at the National Institutes of Health, examining signal transduction pharmacology. Following his post-doc, Kerry spent three years in drug discovery with a pharmaceutical group before joining Luminex.
Cari McDonald, B.S.
Research Scientist, Pharmaceutical and Infectious Disease Lead
Since joining the team in 2008, Cari has been an integral part of Radix. Her laboratory focus is in assay development, assay validation, and sample analysis in support of pharmaceutical clients. In addition to her laboratory focus, Cari enjoys working with current and potential customers to identify how Radix can help them meet their project goals and requirements. Cari is a member of AAPS, has multiple publications and has presented posters at national conventions.
Cari has more than twenty years of research and development experience in academia and the pharmaceutical industry. After receiving her B.S. degree from Winona State University in cell biology, Cari began working at Solvay Animal Health developing immunoassays in support of vaccine formulation and production. She continued to gain valuable experience working at Mayo Clinic for more than ten years, developing oncolytic therapies using attenuated measles virus in Dr. Evanthia Galanis’s lab and identifying novel prostate cancer markers in Dr. George Klee’s Assay Development Lab.
Félix W. Santiago, Ph.D.
Research Scientist, Validation and Sample Analysis Lead
Since 2015, Félix has focused on the research, development, and validation of immunodiagnostic assays, most recently as part of a biothreat detection group. Félix joined the Radix Biosolutions team in 2017; he looks forward to applying his expertise to provide support to our current and potential customers.
Félix has over 12 years of combined research and development experience in academia and industry environments. Throughout his career he has garnered experience in immunology, virology, microbiology, protein biochemistry, vaccine design, and immunoassay development. After receiving a Ph.D in Immunology from the University of Rochester, Félix sought post doctoral training at the University of Texas Medical Branch. There he focused on the molecular mechanisms of immune evasion employed by tick-borne arboviruses. Félix’s work is highlighted by various NIH sponsored funding awards, a growing number of publications, and multiple presentations at scientific meetings.